University Medical Centre Ljubljana and University Hospital of Maribor Elevate Antimicrobial Stewardship with DoseMeRx

DoseMe, a leader in model-informed precision dosing (MIPD), announced the University Medical Centre Ljubljana and University Hospital of Maribor have implemented DoseMeRx, an innovative therapeutic drug monitoring (TDM) platform. This marks a significant advancement in antimicrobial stewardship in Slovenia.

Proscia’s Growth More Than Doubles As Customers Adopt Enterprise Pathology

Record year comes as the rise of precision medicine drives a surge in demand

Integrated DNA Technologies Names Ajay Gannerkote as New President to Lead Bold Era of Innovation and Growth

Ajay Gannerkote, an experienced healthcare leader with more than 20 years of demonstrated success driving industry growth and transformation, takes helm at global genomics company

Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery

Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics

Chromatin Bioscience’s synthetic promoter supports EsoBiotec’s ESO-T01 CAR-T therapy as it enters the clinic

Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antigen (BCMA) CAR-T candidate to reach the clinical stage and utilises a synthetic promoter designed using Chromatin Bio’s proprietary promoter design platform, chromatinLENS, exclusively for EsoBiotec as part of its innovative approach to immunotherapy.

Coronado Research announce appointment of Jo Marshall as EVP Data Services and Advanced Analytics

Coronado Research is pleased to announce the appointment of Jo Marshall as EVP of Data Services and Advanced Analytics.

STEMart Announces Balloon Catheter Testing Services to Ensure Medical Device Safety and Regulatory Compliance

STEMart introduces Balloon Catheter Testing Services for the development of safe and effective medical devices.

Kindeva Drug Delivery and Emervax Partner To Bring Game Changing Vaccine Administration to Patients

Biofidelity and CellCarta partner to deploy Aspyre® Lung in global clinical trials

Biofidelity and CellCarta have announced a strategic partnership agreement to utilize Biofidelity’s Aspyre® Lung in global clinical trials.

ThirdLaw Molecular Inc. Launches its Groundbreaking Platform for Targeted Drug Discovery with a 4.5-Billion Molecule DNA-Encoded Library of Spiroligomer™ Macromolecules

ThirdLaw Molecular Inc., a targeted drug discovery biotech reimagining molecular therapeutics, today announced the launch of its first DNA-encoded library of 4.5 billion Spiroligomer™ macromolecules. This library provides the Company and prospective partners access to a revolutionary category of molecules and the potential to transform how diseases are diagnosed and treated

From Generative AI and ML to Quantum Computing, Bio-IT World 2025 Showcases Technologies Poised to Accelerate Lifesaving Therapies

Bio-IT World Conference & Expo, the premier annual gathering of 3,000 innovators at the intersection of IT and life sciences, returns to Boston April 2-4, ready to meet participants’ demand for the latest information on cutting-edge technologies like generative AI, machine learning (ML), and quantum computing that promise to shape precision medicine and redefine patient outcomes.

Leica Biosystems and Indica Labs Announce Significant Strategic Investment and Creation of Digital Pathology Platform

Leica Biosystems and Indica Labs today announced that Leica Biosystems has agreed to make a significant strategic investment in Indica Labs.

Quris-AI's Bio-AI Platform Integrated by Merck KGaA, Darmstadt, Germany for Preclinical Small Molecule Drug Safety Evaluation

Following an expanded collaboration between AI innovator Quris-AI and Merck KGaA and a two-year validation study to test clinical safety prediction by identifying drug candidate liver toxicity risks, it was announced this morning that Merck KGaA has adopted the startup's platform to test small molecule drug candidates prior to initiating clinical trials. Quris-AI’s platform integrates advanced AI, machine learning, generative models, patient-on-chip technology, and proprietary data to predict potential drug-induced toxicities better.

ClearNote Health’s Avantect® Multi-Cancer Detection Test Selected as One of Two Noninvasive Blood-Based Technologies for National Cancer Institute’s Vanguard Study

ClearNote Health announced that its Avantect Multi-Cancer Detection Test was selected for the National Cancer Institute’s new Vanguard Study.

ClearNote Health’s Avantect® Test Selected for World’s Largest Study of Pancreatic Cancer Detection in High-Risk Patient Population

ClearNote’s Avantect Pancreatic Cancer test was selected for a large UK NHS study that will include up to 15,000 patient participants recently diagnosed with type 2 diabetes. The Avantect test is a blood-based assay designed to use key epigenomic and genomic signals to detect the earliest indicators of pancreatic cancer.

eClinical Solutions Collaborates with Snowflake to Streamline Data for Life Sciences

Integration between eClinical’s elluminate Clinical Data Cloud and Snowflake offers modern data architecture to power clinical data science and AI, unlock data value for healthcare outcomes

Intelliguard Strengthens Leadership and Launches Client Excellence Organization to Drive Growth and Customer Success

- Intelliguard, a leading provider of medication, inventory management and data-intelligence solutions, today announced the appointment of Giovanni Sapio as Chief Financial Officer, along with several other key executive leadership changes. These strategic moves mark a significant milestone in Intelliguard's growth journey, coinciding with the launch of its Client Excellence Organization, designed to further elevate client satisfaction and operational efficiency.

Oxford Nanopore, Action for ME, and University of Edinburgh launch groundbreaking study into the genetics of ME

Oxford Nanopore Technologies will participate in a groundbreaking study will analyse the entire genetic code of up to 17,000 people with Myalgic Encephalomyelitis (ME) in a bid to uncover the genetic causes of the illness.

Concinnity Genetics raises £3m to establish unique RNA-based control systems for precise control of gene therapies in oversubscribed round

Concinnity Genetics, an Edinburgh-based gene control company, is thrilled to announce the closure of its oversubscribed £3m seed funding round. The investment was led by Eos Advisory with support from Scottish Enterprise, Old College Capital (OCC) – the University of Edinburgh’s in-house venture investment fund, and Maven Capital Partners.

BC Platforms-Nottingham Partnership to Power World-Leading University and Hospital Data-Sharing and Research

BC Platforms, a global leader in real-world data, healthcare data management, and analytics, has announced an extended, joint partnership with the University of Nottingham (UoN) and Nottingham University Hospitals NHS Trust (NUH) to provide data-sharing platforms and tools facilitating data sharing, security, and advanced analyses including Trusted Research Environments (TREs*). The outputs of analysing such data, from both clinical and basic research, have the potential to transform our understanding of important healthcare trends, as well as studying devastating diseases such as cancer and diabetes up to the population level. They could also potentially help unlock innovative new solutions and therapies for patients everywhere.